SCHEMBL22917569

SCHEMBL22917569

Cc1cc(/C=C/C(C)C)ccn1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.43
DYRK1A Q13627 1/20 0.37
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP1A1 P04798 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP1B1 Q16678 1/20 0.31
ALOX5 P09917 1/20 0.31
CCR1 P32246 1/20 0.30
CCR5 P51681 1/20 0.30
CCR8 P51685 1/20 0.30
NFE2L2 Q16236 1/20 0.30
KDM1A O60341 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18676897 0.81 UHRF1 (0.37) UHRF1
SCHEMBL9798181 0.78 UHRF1 (0.48) UHRF1DYRK1AALDH1A1MAPTHPGD
SCHEMBL14153950 0.78 UHRF1 (0.48) UHRF1DYRK1AALDH1A1MAPTHPGD
SCHEMBL9798174 0.78 UHRF1 (0.48) UHRF1DYRK1AALDH1A1MAPTHPGD
SCHEMBL17053203 0.76 UHRF1 (0.46) UHRF1DYRK1AALDH1A1MAPTHPGD
SCHEMBL9000347 0.74 UHRF1 (0.45) UHRF1DYRK1AALDH1A1MAPTHPGD
SCHEMBL13754945 0.74 GRM4 (0.53) UHRF1ALDH1A1HPGDSMN1; SMN2CYP1A1
SCHEMBL2958768 0.73 UHRF1 (0.43) UHRF1DYRK1AMAPTSMN1; SMN2ALOX5
SCHEMBL20860597 0.73 XDH (0.44) UHRF1DYRK1AALDH1A1MAPTALOX5
SCHEMBL17085656 0.73 UHRF1 (0.43) UHRF1DYRK1AMAPTSMN1; SMN2ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
US-11345713-B2 Compounds as modulators of TLR2 signaling NEUROPORE THERAPIES, INC. (US) 2022-05-31 US disclosed
US-20210024539-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING NEUROPORE THERAPIES, INC. (US) 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS MAPT, HTT, PSEN1 UHRF1 3628/4885DYRK1A 3524/4885ALDH1A1 4342/4885
US-11345713-B2 Compounds as modulators of TLR2 signaling TLR2, TLR4, TLR3 UHRF1 3724/4885DYRK1A 4021/4885ALDH1A1 4464/4885
US-20210024539-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING TLR2, TLR4, TLR3 UHRF1 3724/4885DYRK1A 4021/4885ALDH1A1 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.